{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:12:24Z","timestamp":1785294744878,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s11864-019-0613-x","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T06:02:40Z","timestamp":1550124160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Use of Immune Checkpoint Inhibitors in Mesothelioma"],"prefix":"10.1007","volume":"20","author":[{"given":"Patrick M.","family":"Forde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"613_CR1","unstructured":"NCCN: NCCN Malignant Pleural Mesothelioma guidelines in https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpm_blocks.pdf (ed), 2018."},{"key":"613_CR2","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1200\/JCO.2004.10.071","volume":"22","author":"W Weder","year":"2004","unstructured":"Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004;22:3451\u20137.","journal-title":"J Clin Oncol"},{"key":"613_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/JTO.0b013e31816fca1b","volume":"3","author":"HF Batirel","year":"2008","unstructured":"Batirel HF, Metintas M, Caglar HB, Yildizeli B, Lacin T, Bostanci K, et al. Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol. 2008;3:499\u2013504.","journal-title":"J Thorac Oncol"},{"key":"613_CR4","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1093\/annonc\/mdm093","volume":"18","author":"W Weder","year":"2007","unstructured":"Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18:1196\u2013202.","journal-title":"Ann Oncol"},{"key":"613_CR5","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","volume":"27","author":"LM Krug","year":"2009","unstructured":"Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007\u201313.","journal-title":"J Clin Oncol"},{"key":"613_CR6","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jtcvs.2006.03.068","volume":"132","author":"RM Flores","year":"2006","unstructured":"Flores RM, Akhurst T, Gonen M, Zakowski M, Dycoco J, Larson SM, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2006;132:763\u20138.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"613_CR7","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1183\/09031936.00039510","volume":"36","author":"PE Schil Van","year":"2010","unstructured":"Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010;36:1362\u20139.","journal-title":"Eur Respir J"},{"key":"613_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.lungcan.2007.02.004","volume":"57","author":"F Rea","year":"2007","unstructured":"Rea F, Marulli G, Bortolotti L, Breda C, Favaretto AG, Loreggian L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer. 2007;57:89\u201395.","journal-title":"Lung Cancer"},{"key":"613_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-2407-13-22","volume":"13","author":"R Federico","year":"2013","unstructured":"Federico R, Adolfo F, Giuseppe M, Lorenzo S, Martino DPT, Anna C, et al. Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma. BMC Cancer. 2013;13:22.","journal-title":"BMC Cancer"},{"key":"613_CR10","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S1470-2045(12)70126-2","volume":"13","author":"A Thomas","year":"2012","unstructured":"Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012;13:e301\u201310.","journal-title":"Lancet Oncol"},{"key":"613_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1183\/09031936.00063109","volume":"35","author":"A Scherpereel","year":"2010","unstructured":"Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35:479\u201395.","journal-title":"Eur Respir J"},{"key":"613_CR12","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","volume":"73","author":"I Woolhouse","year":"2018","unstructured":"Woolhouse I, Bishop L, Darlison L, de Fonseka D, Edey A, Edwards J, et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73:i1\u2013i30.","journal-title":"Thorax"},{"key":"613_CR13","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","volume":"36","author":"HL Kindler","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1343\u201373.","journal-title":"J Clin Oncol"},{"key":"613_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","volume":"75","author":"PA Zucali","year":"2012","unstructured":"Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collov\u00e0 E, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012;75:360\u20137.","journal-title":"Lung Cancer"},{"key":"613_CR15","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","volume":"19","author":"A Scherpereel","year":"2018","unstructured":"Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 2018;19:e161\u201372.","journal-title":"Lancet Oncol"},{"key":"613_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475\u201388.","journal-title":"Nat Rev Cancer"},{"key":"613_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"\u2022\u2022 Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18:623\u201330 Led to the NCCN guidelines to include pembrolizumab as a salvage treatment option for malignant mesothelioma.","journal-title":"Lancet Oncol"},{"key":"613_CR18","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","volume":"18","author":"M Maio","year":"2017","unstructured":"\u2022 Maio M, Scherpereel A, Calabro L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18:1261\u201373 First large trial of a CTLA-4 inhibitor in salvage mesothelioma which did not show a survival benefit over placebo.","journal-title":"Lancet Oncol"},{"key":"613_CR19","unstructured":"Mansfield AS, Peikert T, Smadbeck JB, et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J Thorac Oncol. 2018;10."},{"key":"613_CR20","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","volume":"13","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, et al. Programmed death 1 blockade with Nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13:1569\u201376.","journal-title":"J Thorac Oncol"},{"key":"613_CR21","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Nakano T, Okada M, Kijima T, et al. Long-term efficacy and safety of nivolumab in second- or third-line Japanese malignant pleural mesothelioma patients (phase II: MERIT study). , in IASLC (ed): 19th IASLC World Conference on Lung Cancer Toronto, Canada, 2018. Led to regulatory approval in Japan for nivolumab in salvage therapy for malignant mesothelioma.","DOI":"10.1016\/j.jtho.2018.08.275"},{"key":"613_CR22","unstructured":"Desai A, Karrison T, Rose B, et al. Phase II trial of pembrolizumab (NCT02399371) in previously treated malignant mesothelioma: final analysis., in IASLC (ed): 19th IASLC World Conference on Lung Cancer Toronto, Canada, 2018."},{"key":"613_CR23","unstructured":"Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen F, Delord JP, Dowlati A, Kochuparambil ST, Taylor MH, Powderly JD, Vaishampayan UN, Verschraegen CF, Grote HJ, von Heydebreck A, Chin KM, Gulley JL. Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow up from the JAVELIN solid tumor study. In Oncology JoC (ed): ASCO. Chicago, Illinois, 2018."},{"key":"613_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","volume":"6","author":"L Calabro","year":"2018","unstructured":"Calabro L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6:451\u201360.","journal-title":"Lancet Respir Med"},{"key":"613_CR25","unstructured":"\u2022\u2022 Scherpereel A MJ, Greillier L, et al. Second- or third-line nivolumab or nivolumab plus ipilimumab in malignant pleural mesothelioma patients: results of the IFCT-1501 MAPS2 randomised non-comparative phase 2 trial. Lancet Oncol in press, 2018. Led to the inclusion of nivolumab with and without ipilimumab in salvage therapy for malignant mesothelioma."},{"key":"613_CR26","unstructured":"Disselhorst MJQ-JJ, Lalezari F, et al. Phase II trial of nivolumab and ipilimumab in patients with malignant mesothelioma: Lancet Respir Med in press; 2018."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-019-0613-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0613-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0613-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T21:22:03Z","timestamp":1662931323000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-019-0613-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1007\/s11864-019-0613-x","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"14 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Patrick M. Forde has received a research funding from AstraZeneca, Bristol-Myers Squibb, Corvus, Kyowa Kirin, and Novartis and has received compensation from AbbVie, Astra Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, EMD Serono, Inivata, Eli Lilly, Merck, and Novartis for the service on advisory boards and\/or as a consultant.Arnaud Scherpereel has received a research funding (paid to his institution) from Bristol-Myers Squibb and MSD; has received a compensation from AstraZeneca, Bristol-Myers Squibb, MSD, and Roche for participation on advisory boards and\/or lectures provided; and has received a travel support to international meetings on thoracic oncology from Bristol-Myers Squibb, MSD, and Roche.Anne S. Tsao has received a research funding from Bristol-Myers Squibb, Genentech\/Roche, Eli Lilly, Millennium, Seattle Genetics, Ariad, Boehringer Ingelheim, Polaris, Epizyme, Merck, AstraZeneca, and Takeda and has received compensation from Bristol-Myers Squibb, Genentech\/Roche, Ariad, Boehringer Ingelheim, AstraZeneca, and Takeda for the participation on advisory boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"18"}}